Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Chemotherapy-induced cardiotoxicity and mitigation
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the cardiotoxic effects of various cancer treatments, particularly anthracyclines and related drugs like doxorubicin and trastuzumab. It explores the molecular mechanisms, pharmacologic developments, early detection, prevention, and management of cardiotoxicity in cancer patients. The papers also discuss the long-term cardiovascular complications and survival outcomes in individuals undergoing these treatments.
142
Works
IDs:OpenAlex
How has Chemotherapy-induced cardiotoxicity and mitigation's publication output changed over time?
ScholarIQpublication output · 1982–2022
Output grew0% over the shown period — from 1 works in 1982 to 1 in 2022.
1
1
2
1
1
1
2
4
1
1
1982200220102011201220132016202020212022
What are the most-cited papers on Chemotherapy-induced cardiotoxicity and mitigation?
ScholarIQmost cited works
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Alexander R. Lyon, Teresa López‐Fernández, Liam S. Couch, Riccardo Asteggiano, Marianne Aznar, Jutta Bergler‐Klein, Giuseppe Boriani, Daniela Cardinale, Raúl Córdoba, Bernard Cosyns, David J. Cutter, Evandro de Azambuja, Rudolf A. de Boer, Susan Dent, Dimitrios Farmakis, Sofie Gevaert, Diana A. Gorog, Joerg Herrmann, Daniel J. Lenihan, Javid J. Moslehi, Brenda Moura, Sonja S Salinger, Richard Stephens, Thomas Suter, Sebastian Szmit, Juan Tamargo, Paaladinesh Thavendiranathan, Carlo G. Tocchetti, Peter van der Meer, Helena J. H. van der Pal, ESC Scientific Document Group, Patrizio Lancellotti, Franck Thuny, Magdy Abdelhamid, Victor Aboyans, Berthe M.P. Aleman, Joachim Alexandre, Ana Barac, Michael A Borger, Rubén Casado-Arroyo, Jennifer Cautela, Jolanta Čelutkienė, Maja Čikeš, Alain Cohen‐Solal, Kreena Dhiman, Stéphane Éderhy, Thor Edvardsen, Laurent Fauchier, Michael G. Fradley, Julia Grapsa, Sigrun Halvorsen, Michael Heuser, Marc Humbert, Tiny Jaarsma, Thomas Kahan, Aleksandra Konradi, Konstantinos C Koskinas, Dipak Kotecha, Bonnie Ky, Ulf Landmesser, Basil S Lewis, Aleš Linhart, Gregory Y H Lip, Maja‐Lisa Løchen, Katarzyna Małaczyńska-Rajpold, Marco Metra, Richard Mindham, Marie Moonen, Tomas G. Neilan, Jens Cosedis Nielsen, Anna-Sonia Petronio, Eva Prescott, Amina Rakisheva, Joe‐Elie Salem, Gianluigi Savarese, Marta Sitges, Jurriën M. ten Berg, Rhian M. Touyz, Agnieszka Tycińska, Matthias Wilhelm, José Luis Zamorano, Nadia Laredj, Parounak Zelveian, Peter P. Rainer, Fuad Samadov, Uladzimir Andrushchuk, Bernhard Gerber, Mirsad Selimović, Elena Kinova, Jure Samardžić, Evagoras Economides, Radek Pudil, Kirsten M Nielsen, Tarek A Kafafy, Riina Vettus, Suvi Tuohinen, Stéphane Éderhy, Zurab Pagava, Tienush Rassaf, Αlexandros Briasoulis
European Heart Journal. 20222,870 CitationsOPEN ACCESS
Doxorubicin pathways
Caroline F. Thorn, Connie Oshiro, Sharon Marsh, Tina Hernandez‐Boussard, Howard L. McLeod, Teri E. Klein, Russ B. Altman
S192301155. 20101,637 CitationsOPEN ACCESS
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Andrew D. Seidman, Clifford A. Hudis, Mary Kathryn Pierri, Steven Shak, Virginia Paton, Mark Ashby, Maureen Murphy, Stanford J. Stewart, Deborah Keefe
Journal of Clinical Oncology. 20021,509 Citations
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Giuseppe Curigliano, Daniel J. Lenihan, Michael G. Fradley, Sarju Ganatra, Ana Barac, Anne Blaes, J. Herrmann, Charles Porter, Alexander R. Lyon, P Lancellotti, Aarti Patel, Jeanne M. DeCara, Joshua D. Mitchell, Eric Harrison, Javid J. Moslehi, Ronald Witteles, Maria Grazia Calabró, Roberto Orecchia, Evandro de Azambuja, J. L. Zamorano, Ronald J. Krone, Zaza Iakobishvili, Joseph R. Carver, Saro H. Armenian, Bonnie Ky, Daniela Cardinale, Carlo M. Cipolla, Susan Dent, Karin Jordan
Annals of Oncology. 20201,022 CitationsOPEN ACCESS
Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
Heloisa Sawaya, Igal A. Sebag, Juan Carlos Plana, James L. Januzzi, Bonnie Ky, Timothy C. Tan, Victor Cohen, José Banchs, Joseph R. Carver, Susan E. Wiegers, Randolph P. Martin, Michael H. Picard, Robert E. Gerszten, Elkan F. Halpern, Jonathan Passeri, Irene Kuter, Marielle Scherrer‐Crosbie
S110626636. 2012822 CitationsOPEN ACCESS
Where is Chemotherapy-induced cardiotoxicity and mitigation research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Chemotherapy-induced cardiotoxicity and mitigation is open access?
ScholarIQopen access share
73%OPEN ACCESS
Gold
7%
Green
40%
Hybrid
13%
Bronze
13%
Closed
27%
Related on ScholarIQ
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
Paper
Doxorubicin pathways
Paper
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Paper
Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations
Paper
Rates of Initial and Recurrent Thromboembolic Disease Among Patients with Malignancy Versus Those without Malignancy: Risk Analysis Using Medicare Claims Data
Paper
American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Paper